Helena Escuin-Ordinas

8.1k citations

19 papers · 2.1k indexed · 1 hit paper · h-index 13

Oncology top 2%
Immunology top 2%
Molecular Biology
Pulmonary and Respiratory Medicine top 10%
Cancer Research top 10%

Co-authors: Antoni Ribas Begonya Comin-Anduix Thomas G. Graeber Roger S. Lo Willy Hugo Siwen Hu‐Lieskovan Jesse M. Zaretsky Lu Sun
Topics: Cancer Immunotherapy and Biomarkers (7 papers)CAR-T cell therapy research (6 papers)Immunotherapy and Immune Responses (6 papers)
Cited by: Oncology Immunology Cancer Research
Journals: Nucleic Acids Research PLoS ONE Cancer Research
Partner nations: United States United Kingdom Spain

In The Last Decade

Helena Escuin-Ordinas

19 papers receiving 2.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Interferon Receptor Signaling Pathways Regulating PD-L1 and PD-L2 Expression

2017 1.3k citations Ángel García-Díaz, Daniel Sanghoon Shin et al. Cell Reports profile →

Peers

Countries citing papers authored by Helena Escuin-Ordinas

Since Specialization

Citations

This map shows the geographic impact of Helena Escuin-Ordinas's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Helena Escuin-Ordinas with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Helena Escuin-Ordinas more than expected).

Fields of papers citing papers by Helena Escuin-Ordinas

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Helena Escuin-Ordinas. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Helena Escuin-Ordinas. The network helps show where Helena Escuin-Ordinas may publish in the future.

Co-authorship network of co-authors of Helena Escuin-Ordinas

This figure shows the co-authorship network connecting the top 25 collaborators of Helena Escuin-Ordinas. A scholar is included among the top collaborators of Helena Escuin-Ordinas based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Helena Escuin-Ordinas. Helena Escuin-Ordinas is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

19 of 19 papers shown

#	Work	Indexed citations
1	Intratumoral BO-112 in combination with radiotherapy synergizes to achieve CD8 T-cell-mediated local tumor control 2023 ·Journal for ImmunoTherapy of Cancer ·María E. Rodríguez-Ruiz,(unknown),(unknown),Paloma Sánchez‐Mateos,(unknown),(unknown),(unknown),(unknown),Maite Álvarez,Miguel F. Sanmamed,José Luis Perez‐Gracia,Helena Escuin-Ordinas,Marisol Quintero,Ignacio Melero	14
2	Abstract CT221: A phase I study of intratumoral BO-112 and nivolumab for resectable soft tissue sarcoma 2021 ·Cancer Research ·Anusha Kalbasi,Fritz C. Eilber,Arun S. Singh,Bartosz Chmielowski,Nicholas M. Bernthal,Brooke Crawford,Joseph G. Crompton,Varand Ghazikhanian,Leanne L. Seeger,Kambiz Motamedi,Michael Douek,Carol Felix,Vincent Basehart,Helena Escuin-Ordinas,Marisol Quintero,(unknown)	2
3	Wound healing with topical BRAF inhibitor therapy in a diabetic model suggests tissue regenerative effects 2021 ·PLoS ONE ·Helena Escuin-Ordinas,Yining Liu,Lu Sun,Willy Hugo,Robert Dimatteo,Rong Huang,Paige Krystofinski,Ariel M. Azhdam,Jordan Lee,Begoña Comı́n-Anduix,Alistair J. Cochran,Roger S. Lo,Tatiana Segura,Philip O. Scumpia,Antoni Ribas	10
4	Accelerated wound healing by injectable star poly(ethylene glycol)-b-poly(propylene sulfide) scaffolds loaded with poorly water-soluble drugs 2018 ·Journal of Controlled Release ·Suwei Zhu,Shuoran Li,Helena Escuin-Ordinas,Robert Dimatteo,Weixian Xi,Antoni Ribas,Tatiana Segura	37
5	Characterization of Postinfusion Phenotypic Differences in Fresh Versus Cryopreserved TCR Engineered Adoptive Cell Therapy Products 2018 ·Journal of Immunotherapy ·Theodore S. Nowicki,Helena Escuin-Ordinas,Earl Avramis,Bartosz Chmielowski,Thinle Chodon,Beata Berent-Maoz,Xiaoyan Wang,Paula Kaplan‐Lefko,Lili Yang,David Baltimore,James S. Economou,Antoni Ribas,Begoña Comı́n-Anduix	2
6	Interferon Receptor Signaling Pathways Regulating PD-L1 and PD-L2 Expressionbreakdown → 2017 ·Cell Reports ·Ángel García-Díaz,Daniel Sanghoon Shin,Blanca Homet Moreno,Justin D. Saco,Helena Escuin-Ordinas,Gabriel Abril Rodriguez,Jesse M. Zaretsky,Lu Sun,Willy Hugo,Xiaoyan Wang,Giulia Parisi,Cristina Puig-Saus,Davis Y. Torrejon,Thomas G. Graeber,Begonya Comin-Anduix,Siwen Hu‐Lieskovan,Robert Damoiseaux,Roger S. Lo,Antoni Ribas	1327
7	Abstract NG04: Mechanisms of resistance to anti-PD-1 immunotherapy through interferon pathway mutations 2017 ·Cancer Research ·Jesse M. Zaretsky,Ángel García-Díaz,Daniel S. Shin,Helena Escuin-Ordinas,Willy Hugo,Siwen Hu‐Lieskovan,Zeynep Eroglu,Davis Y. Torrejon,Paul C. Tumeh,Roger S. Lo,Antoni Ribas	3
8	Tremelimumab: research and clinical development 2016 ·OncoTargets and Therapy ·F. Javier Ibarrondo,Begonya Comin-Anduix,Helena Escuin-Ordinas	75
9	An Effective Immuno-PET Imaging Method to Monitor CD8-Dependent Responses to Immunotherapy 2015 ·Cancer Research ·Richard Tavaré,Helena Escuin-Ordinas,Stephen Mok,Melissa McCracken,Kirstin A. Zettlitz,Felix B. Salazar,Owen N. Witte,Antoni Ribas,Anna M. Wu	237
10	Combination of pan-RAF and MEK inhibitors in NRAS mutant melanoma 2015 ·Molecular Cancer ·Mohammad Atefi,Bjoern Titz,Earl Avramis,Charles Ng,Deborah J. Wong,Amanda Lassen,Michael Cerniglia,Helena Escuin-Ordinas,David Foulad,Begonya Comin-Anduix,Thomas G. Graeber,Antoni Ribas	51
11	Detection of antibody therapy-induced anti-tumor immune responses using anti-CD8 immuno-pet 2015 ·Journal for ImmunoTherapy of Cancer ·Richard Tavaré,Helena Escuin-Ordinas,Melissa McCracken,Kirstin A. Zettlitz,Felix B. Salazar,Owen N. Witte,Antoni Ribas,Anna M. Wu	1
12	Innate resistance of PD-1 blockade through loss of function mutations in JAK resulting in inability to express PD-L1 upon interferon exposure 2015 ·Journal for ImmunoTherapy of Cancer ·Daniel S. Shin,Ángel García-Díaz,Jesse M. Zaretsky,Helena Escuin-Ordinas,Siwen Hu‐Lieskovan,Nicolaos Palaskas,Willy Hugo,(unknown),Bartosz Chmielowski,Grace Cherry,Beata Berent-Maoz,Thomas G. Graeber,Roger S. Lo,Begonya Comin-Anduix,Antoni Ribas	14
13	Exposure to a Histone Deacetylase Inhibitor Has Detrimental Effects on Human Lymphocyte Viability and Function 2014 ·Cancer Immunology Research ·Deborah J. Wong,(unknown),Earl Avramis,Douglas Matsunaga,Kimberly M. Komatsubara,Mohammad Atefi,Helena Escuin-Ordinas,Thinle Chodon,Richard C. Koya,Antoni Ribas,Begoña Comı́n-Anduix	17
14	APE-Type Non-LTR Retrotransposons of Multicellular Organisms Encode Virus-Like 2A Oligopeptide Sequences, Which Mediate Translational Recoding during Protein Synthesis 2013 ·Molecular Biology and Evolution ·Valerie Odon,Garry A. Luke,(unknown),Pablo de Felipe,Lin Ruan,Helena Escuin-Ordinas,Jeremy D. Brown,Martin D. Ryan,(unknown)	11
15	COX‐2 inhibition prevents the appearance of cutaneous squamous cell carcinomas accelerated by BRAF inhibitors 2013 ·Molecular Oncology ·Helena Escuin-Ordinas,Mohammad Atefi,Yong Fu,Ashley Cass,Charles Ng,Rong Huang,Sharona Yashar,Begonya Comin-Anduix,Earl Avramis,Alistair J. Cochran,Richard Marais,Roger S. Lo,Thomas G. Graeber,Harvey R. Herschman,Antoni Ribas	31
16	PET imaging to non-invasively study immune activation leading to antitumor responses with a 4-1BB agonistic antibody 2013 ·Journal for ImmunoTherapy of Cancer ·Helena Escuin-Ordinas,Mark Elliott,Mohammad Atefi,Michelle Lee,Charles Ng,Wei Liu,Begoña Comı́n-Anduix,Encarnacion Montecino‐Rodriguez,Earl Avramis,Caius G. Radu,Leslie L. Sharp,Antoni Ribas	14
17	2A peptides provide distinct solutions to driving stop-carry on translational recoding 2011 ·Nucleic Acids Research ·(unknown),Fu Yan,Victoria A. Doronina,Helena Escuin-Ordinas,Martin D. Ryan,Jeremy D. Brown	111
18	Modulation of Cell Signaling Networks after CTLA4 Blockade in Patients with Metastatic Melanoma 2010 ·PLoS ONE ·Begoña Comı́n-Anduix,Hooman Sazegar,Thinle Chodon,Douglas Matsunaga,Jason Jalil,Erika von Euw,Helena Escuin-Ordinas,Robert Balderas,Bartosz Chmielowski,Jesús Gómez-Navarro,Richard C. Koya,Antoni Ribas	23
19	The Oncogenic BRAF Kinase Inhibitor PLX4032/RG7204 Does Not Affect the Viability or Function of Human Lymphocytes across a Wide Range of Concentrations 2010 ·Clinical Cancer Research ·Begoña Comı́n-Anduix,Thinle Chodon,Hooman Sazegar,Douglas Matsunaga,Stephen Mock,Jason Jalil,Helena Escuin-Ordinas,Bartosz Chmielowski,Richard C. Koya,Antoni Ribas	111

About Helena Escuin-Ordinas

Helena Escuin-Ordinas is a scholar working on Oncology, Immunology and Rehabilitation, having authored 19 papers that have together received 2.1k indexed citations. Recurring topics across this work include Cancer Immunotherapy and Biomarkers (7 papers), CAR-T cell therapy research (6 papers) and Immunotherapy and Immune Responses (6 papers). The work is most often cited by research in Oncology (1.4k citations), Immunology (1.0k citations) and Cancer Research (175 citations). Helena Escuin-Ordinas has collaborated with scholars based in United States, United Kingdom and Spain. Frequent co-authors include Antoni Ribas, Begonya Comin-Anduix, Thomas G. Graeber, Roger S. Lo, Willy Hugo, Siwen Hu‐Lieskovan, Jesse M. Zaretsky, Lu Sun, Ángel García-Díaz and Xiaoyan Wang. Their work appears in journals such as Nucleic Acids Research, PLoS ONE and Cancer Research.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact